Skip to main content

Table 2 Demographic characteristics, cognitive test scores, APO E allele distribution, brain volumetric measures, and cerebrospinal fluid biomarkers at baseline and follow-up for the final analysis set (115 MCI subjects) and the two groups MCI-stable and MCI-AD

From: Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

  All (n = 115) MCI-stable (n = 87) MCI-AD (n = 28) Standard mean difference* P value**
Age (years) 65.7 ± 9.03
(36–89)
66.5 ± 8.95
(51–80)
65.4 ± 9.37
(36–89)
0.12 ns
Education (years schooling) 9.50 ± 1.91
(7–13)
9.75 ± 1.95
(7–13)
8.75 ± 1.58
(7–13)
–0.52 <0.05
Gender (female = 1, male = 2) Male = 67;
female = 48
Male = 52;
female = 35
Male = 15;
female = 13
0.13 ns
Bayer-ADL scale (score: 1–10) 2.47 ± 1.48
(1–4)
2.41 ± 1.52
(1–4)
2.67 ± 1.34
(1–4)
0.18 ns
MADRS (score: 0–60) 7.41 ± 5.75
(0–13)
7.67 ± 5.96
(0–13)
6.62 ± 5.08
(0–11)
–0.18 ns
MMSE 27.0 ± 2.12
(20–30)
27.5 ± 1.87
(22–30)
25.8 ± 2.34
(20–29)
–0.81 <0.001
CDR-sb 1.80 ± 1.06
(0.5–4.5)
1.59 ± 1.00
(0.5–4.5)
2.45 ± 0.98
(0.5–4)
0.81 <0.001
CERAD-DR-WL 4.82 ± 2.33
(0–10)
5.25 ± 2.23
(0–10)
3.46 ± 2.15
(0–8)
–0.77 0.001
Amnestic deficit: CERAD-DR-WL below cut-off (<7 correct responses), n (% present) 88 (77%) 62 (71%) 26 (93%)   
ApoE4 alleles (homo- or heterozygotes), n/sample size (% present) 41/103 (40%) 32/78 (41%) 9/25 (36%)   ns
Hippocampal volume (mm3) 4450 ± 672
(2509–5996)
4585 ± 649
(3036–5996)
4031 ± 570
(2509–5235)
–0.82 <0.0001
Total tau in CSF (pg/ml) 411 ± 252
(112–1169)
351 ± 205
(112–1158)
596 ± 294
(156–1169)
0.97 <0.0001
Total tau in CSF below cut-off (>300 pg/ml), n (% abnormal) 65 (57%) 41 (47%) 24 (86%)   
Phosphorylated tau in CSF (pg/ml) 61.3 ± 30.5
(19.7–157)
55.6 ± 26.3
(19.7–130)
78.8 ± 36.1
(27.3–157)
0.76 <0.01
Phosphorylated tau in CSF below cut-off (>60 pg/ml), n (% abnormal) 44 (38%) 27 (31%) 17 (61%)   
Aβ42 in CSF (pg/ml) 749 ± 300
(245–1792)
794 ± 309
(276–1792)
611 ± 223
(245–1134)
–0.61 <0.001
Aβ42 in CSF below cut-off (<600 pg/ml), n (% abnormal) 39 (34%) 22 (25%) 17 (61%)   
Aβ40 in CSF (pg/ml) 9654 ± 2731
(2604–16320)
9601 ± 2561
(4175–16320)
9817 ± 3251
(2604–15210)
0.08 ns
Aβ40 in CSF below cut-off, n (% abnormal) n/a n/a n/a   
Follow-up time (months) 25.5 ± 9.8
(12–36)
26.1 ± 8.0
(12–36)
25.2 ± 8.9
(12–36)
  ns
  1. Values are given as means ± SD (range) unless otherwise stated
  2. *Standardized (mean values in MCI-AD patients – mean values in MCI-stable patients)/standard deviation in the group of all patients
  3. **P values refer to differences between MCI-stable and MCI-AD
  4. Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, AD Alzheimer’s disease, B-ADL Bayer activities of daily living, CDR-sb Clinical Dementia Rating–sum-of-boxes, CERAD-DR-WL Consortium to Establish a Registry of Dementia–delayed recall word list, CSF cerebrospinal fluid, MADRS Montgomery-Asberg Depression Rating Scale, MCI cognitive impairment, MMSE Mini-Mental State Examination, n/a not available, ns not significant